Skip to content
Trichlormethiazide
Metahydrin, Metatensin, Naqua, Naquival, Trichlorex, Trichlormas (trichlormethiazide) is a small molecule pharmaceutical. Trichlormethiazide was first approved as Metatensin #2 on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Reserpine
+
Trichlormethiazide
Tradename
Company
Number
Date
Products
METATENSIN #2SanofiN-012972 DISCN1982-01-01
1 products
METATENSIN #4SanofiN-012972 DISCN1982-01-01
1 products
NAQUIVALMerck Sharp & DohmeN-012265 DISCN1982-01-01
1 products
Hide discontinued
Trichlormethiazide
Tradename
Company
Number
Date
Products
METAHYDRINSanofiN-012594 DISCN1988-06-16
2 products
NAQUAMerck Sharp & DohmeN-012265 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
edema—D004487R60.9
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
nephrotic syndromeEFO_0004255D009404N04
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03A: Low-ceiling diuretics, thiazides
— C03AA: Thiazides, plain
— C03AA06: Trichlormethiazide
— C03AB: Thiazides and potassium in combination
— C03AB06: Trichlormethiazide and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA02: Trichlormethiazide and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ProteinuriaD011507HP_0000093R80———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10——1—12
Cardiovascular diseasesD002318EFO_0000319I98——1——1
Heart diseasesD006331EFO_0003777I51.9——1——1
Sudden death cardiacD016757EFO_0004278——1——1
Heart arrestD006323EFO_0009492I46——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRICHLORMETHIAZIDE
INNtrichlormethiazide
Description
Trichlormethiazide is a benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension. It has a role as a diuretic and an antihypertensive agent. It is a benzothiadiazine and a sulfonamide antibiotic.
Classification
Small molecule
Drug classdiuretics (thiazide derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
Identifiers
PDB—
CAS-ID133-67-5
RxCUI10772
ChEMBL IDCHEMBL1054
ChEBI ID9683
PubChem CID5560
DrugBankDB01021
UNII IDQ58C92TUN0 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 396 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,514 adverse events reported
View more details